Skip to main content

PROMINENT

Co-led by Professor Allan Balmain (University of California, San Francisco, USA), Dr Paul Brennan (International Agency for Research on Cancer, France) and Professor Nuria Lopez-Bigas (Institute for Research in Biomedicine, Spain).

The challenge

PROMINENT is tackling the normal phenotypes challenge. While the accumulation of mutations has long been considered the primary trigger of tumorigenesis, when the challenge was set in 2020, it was becoming clear it wasn’t always that simple. It was becoming increasingly evident that cells often carry many known cancer-causing mutations yet remain phenotypically normal and do not form tumours. The PROMINENT team set out to investigate a hypothesis about the very early stages of cancer development, the promoter hypothesis, in which cells exposed to mutagenic carcinogens accumulate cancer-driving mutations but remain dormant. Only after exposure to a ‘promoting’ stimulus, such as chronic wounding, do these ‘initiated’ cells, through an unknown mechanism, gain a selective advantage allowing them to undergo clonal expansion and progress to malignancy. The team plan to build a ‘roadmap’ as a cell travels along this pathway to transformation, looking for opportunities to intervene at the critical moment of transition and find new routes to prevention and treatment.

At a glance

Funded in 2022
Institutions 6
Locations UK, US, France, Spain
Specialisms epidemiology, genomics, animal modelling, machine learning, community engagement and cancer prevention

Team and leadership

PROMINENT is co-led by:

Professor Allan Balmain

Dr Paul Brennan

Professor Nuria Lopez-Bigas

The PROMINENT team brings together advocates and scientists with expertise in epidemiology and human interventional studies, computational biology, mouse and organoid models, genetics and multi-omics imaging, across five institutions in Spain, France, and the US.

Tackling the normal phenotypes challenge

PROMINENT is broadly considering what makes a cell ‘normal’, focusing on lung, kidney, oesophagus, bladder, pancreas and colorectal tissues, the team aims to answer four major questions:

  1. What are the environmental, lifestyle or endogenous risk factors that promote the selection of pre-initiated cells in normal tissue? 
  1. Which cells carry initiating mutations, where are they located, how are they selected for during ageing, and what is their relationship with normal and cancer stem cells? 
  1. Which mechanisms promote the first signs of neoplastic growth, and what additional changes cause transition to full malignancy? 
  1. How can we intervene to prevent the earliest stages of neoplastic cell selection by tumour promoters? 

PROMINENT is leveraging a unique collection of resources, including more than 4,000 mouse samples spanning all stages of carcinogenesis and an extensively annotated collection of human tumour and matched healthy tissue samples from over 5,000 participants across 20 countries. Many of these samples were generated through the earlier Cancer Grand Challenges team Mutographs, providing a rich foundation for studying cancer-promoting processes. By combining longitudinal human studies, organoid and mouse models, multi-omics approaches, and advanced computational analyses, the team aims to identify the molecular mechanisms and signatures that drive cancer promotion.

The team is well underway in addressing the above questions. In models that better capture the complexity of human cancer development, combining genetic diversity, exposure to mutagens and tumour-promoting factors, the team investigated the controversial role of stem cells in cancer development. It utilised a network approach to look at the expression of stem cells genes in single cells, and how these networks evolve during carcinogenesis. They revealed two main cell states, which can converge, a high plasticity stem cell state and a proliferating state, highlighting that the switch between these states may control progression and drug resistance. Also in skin, the team showed that normal cells can accumulate thousands of mutations and persist for decades without becoming cancerous, with promotion the rate-limiting step to transformation. This work also highlighted that obesity likely acts as a promoter, with no increase in mutations observed. The team further showed that promotion alters the competitive landscape within normal tissues, driving the expansion of specific mutant clones, including Hras-mutant populations, and revealing how environmental signals can manipulate clonal dynamics to influence cancer risk.

Using ultradeep DNA duplex sequencing to profile normal bladder tissue, the team investigated why bladder cancer is around four times more common in men than women. They found that while mutation rates were very similar between the sexes, certain driver mutations in bladder cancer undergo a stronger selection pressure in men, resulting in clonal expansion. The team also showed that smoking, a well-established risk factor for bladder cancer, was associated not with increased mutational burden but with increased expansion of mutant cell clones, suggesting it acts predominantly as a promoter in this tissue.

Together, these findings demonstrate that cancer risk is determined not only by mutation acquisition, but also by the selective pressures that shape the behaviour of mutant clones in normal tissues. The team has also demonstrated the power of ultradeep sequencing to investigate the earliest stages of cancer evolution.

Harnessing AI through Project AURORA

In 2026, PROMINENT was selected to take part in Project AURORA, a pioneering Cancer Grand Challenges initiative exploring how AI agents could help research teams generate new hypotheses, design experiments and accelerate progress against cancer.

Led by Nuria Lopez-Bigas at the Institute for Research in Biomedicine Barcelona and supported by Emma Lundberg at Stanford University the AURORA PROMINENT pioneer team  will investigate how mutations alter cell behaviour and contribute to tumour development. The co-scientist will generate explanations, assess them against existing datasets and propose laboratory experiments. Automated imaging will reveal how genetic changes affect cells, helping the researchers test and refine these ideas.

The AI co-scientist will draw on scientific literature, genomic data and experimental evidence to propose potential mechanisms for the team to test. The team will then use automated genetic screens and cellular imaging to investigate selected hypotheses. This approach could help PROMINENT move from identifying mutations associated with cancer risk to understanding how they act, supporting its wider ambition to uncover opportunities for early intervention and prevention.

PROMINENT's core programme is funded by Cancer Research UK, the National Cancer Institute and the Scientific Foundation of the Spanish Association Against Cancer through Cancer Grand Challenges. The AURORA project is funded by Cancer Research UK.

Marinka and Nuria
Pictured left to right: Nuria Lopez-Bigas (Co-Team Lead, team PROMINENT), Marinka Zitnik (Project Lead, Project AURORA)

Looking ahead

Going forward, the team will integrate its ultradeep sequencing approaches with spatial proteomic and transcriptomic analyses  map clonal architecture across several normal human tissues and decipher the mechanisms by which different cancer risk factors may act as promoters. The team will extend these studies through human intervention cohorts to directly profile normal tissue responses to promoting exposures.  

By unraveling the intricate interplay between genetic mutations, cellular processes, and environmental factors, the PROMINENT team hopes to bring a new perspective to fundamental questions surrounding early tumour development and identify new opportunities for intervention and routes to prevention. This proactive approach offers hope for a future where cancer is stopped in its tracks.

To learn more, visit PROMINENT's website, which is managed and updated by the team itself.

Allam Balmain
As a research community, we’re on the verge of a major leap forward in our understanding of the factors that contribute to the risk of cancer, which could help to find new, informed ways to stop cancer before it even starts.
Allan Balmain (Co-Team Lead, PROMINENT)
University of California, San Francisco

Members of team PROMINENT